title: The role of surgery for metastatic renal cell carcinoma in the era of targeted therapies.
abstract: OBJECTIVE
  With the emergence of targeted therapies, the indications of cytoreductive nephrectomy have to be redefined. This review article presents the evidence data guiding our current indications of surgery in the management of metastatic renal cell carcinoma (mRCC) in the era of targeted therapies.
  
  
  METHODS
  A nonsystematic review of the electronic databases PubMed and MEDLINE from 1980 to 2012 was performed and limited to English language.
  
  
  RESULTS
  Two studies based on immunotherapy (EORTC 30947 and SWOG 8949) were at the origins of the recommendations on initial nephrectomy for patients with mRCC. Since the introduction of angiogenesis inhibitors, there is still no high-level evidence from prospective studies assessing the indication of surgery for mRCC. However, surgery still has its importance in the management of primary tumors and metastasis with the objective of an optimal balance between morbidity, quality of life, and survival. The treatment sequence between surgery and targeted therapies is still to be established and two randomized prospective studies were then specifically designed and are currently recruiting.
  
  
  CONCLUSIONS
  Preliminary evidence data from retrospective series seem to be in favor of a benefit of surgery for patients with good and intermediate prognosis. However, patients' inclusions in current prospective studies are highly recommended to clearly precise nephrectomy's indications.
authors.affiliation: Department of Urology, Angers University Hospital, Angers, France, pibigot@chu-angers.fr.
authors.forename: Pierre
authors.initials: P
authors.lastname: Bigot
authors.forename: Souhil
authors.initials: S
authors.lastname: Lebdai
authors.forename: Alain
authors.initials: A
authors.lastname: Ravaud
authors.forename: Abdel Rahmène
authors.initials: AR
authors.lastname: Azzouzi
authors.forename: Jean-Marie
authors.initials: JM
authors.lastname: Ferrière
authors.forename: Jean-Jacques
authors.initials: JJ
authors.lastname: Patard
authors.forename: Jean-Christophe
authors.initials: JC
authors.lastname: Bernhard
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use; D002292:Carcinoma, Renal Cell / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D006801:Humans; D007167:Immunotherapy / Q000379:methods; D007680:Kidney Neoplasms / Q000175:diagnosis / Q000473:pathology / Q000628:therapy*; D009362:Neoplasm Metastasis / Q000175:diagnosis / Q000628:therapy*; D009392:Nephrectomy / Q000379:methods*; D011379:Prognosis; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors
references.citation: J Urol. 2011 Feb;185(2):439-44
references.pmid: 21167518
references.citation: J Urol. 2004 Mar;171(3):1071-6
references.pmid: 14767273
references.citation: Eur Urol. 2011 Sep;60(3):448-54
references.pmid: 21612860
references.citation: BJU Int. 2012 Jun;109(12):1807-12
references.pmid: 21951647
references.citation: Eur Urol. 2011 Nov;60(5):964-71
references.pmid: 21621907
references.citation: J Urol. 2004 Jun;171(6 Pt 1):2155-9; discussion 2159
references.pmid: 15126776
references.citation: Prog Urol. 2008 Jul;18 Suppl 4:S69-76
references.pmid: 18706374
references.citation: Urology. 2009 Feb;73(2):342-6
references.pmid: 19041122
references.citation: Curr Opin Oncol. 2012 May;24(3):284-90
references.pmid: 22343386
references.citation: Ann Surg Oncol. 1994 Jul;1(4):345-52
references.pmid: 7850534
references.citation: Oncologist. 2011;16 Suppl 2:45-50
references.pmid: 21346039
references.citation: N Engl J Med. 2001 Dec 6;345(23):1655-9
references.pmid: 11759643
references.citation: J Urol. 2011 Jan;185(1):54-9
references.pmid: 21074811
references.citation: Eur Urol. 2008 Apr;53(4):845-8
references.pmid: 18053636
references.citation: Eur Urol. 2007 Jun;51(6):1502-10
references.pmid: 17408850
references.citation: Eur Urol. 2009 Dec;56(6):998-1003
references.pmid: 19054604
references.citation: N Engl J Med. 2012 Mar 8;366(10):883-892
references.pmid: 22397650
references.citation: Cancer. 2011 Jul 1;117(13):2873-82
references.pmid: 21692048
references.citation: Eur Urol. 2011 Jun;59(6):912-8
references.pmid: 21367518
references.citation: J Urol. 2011 Jan;185(1):60-6
references.pmid: 21074201
references.citation: Ann Oncol. 2012 Oct;23 Suppl 7:vii65-71
references.pmid: 22997456
references.citation: Eur Urol. 2011 Jan;59(1):10-5
references.pmid: 20952123
references.citation: Clin Cancer Res. 2008 Apr 15;14(8):2431-6
references.pmid: 18413834
references.citation: Lancet. 2001 Sep 22;358(9286):966-70
references.pmid: 11583750
references.citation: Urol Oncol. 2015 Aug;33(8):339.e9-15
references.pmid: 26087971
references.citation: N Engl J Med. 1971 Nov 18;285(21):1182-6
references.pmid: 4938153
references.citation: Eur Urol. 2009 Jun;55(6):1477-80
references.pmid: 19150171
references.citation: World J Urol. 2009 Aug;27(4):533-9
references.pmid: 19145434
references.citation: Int J Surg Oncol. 2012;2012:250479
references.pmid: 22778936
references.citation: J Urol. 2007 Mar;177(3):855-60; discussion 860-1
references.pmid: 17296358
references.citation: Prog Urol. 2008 Nov;18 Suppl 7:S298-308
references.pmid: 19070807
references.citation: World J Urol. 2010 Jun;28(3):295-301
references.pmid: 20364382